SCYNEXIS, Inc., a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration...

Biotechnology company, SCYNEXIS, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oral ibrexafungerp for the treatment of vulvovaginal...

SCYNEXIS, Inc. announced this week positive top-line results for its Phase 3 VANISH-306 study investigating the safety and efficacy of oral ibrexafungerp, a novel broad-spectrum antifungal, as a treatment...

Today is World Aspergillosis Day, a day to raise awareness about a fungal infection that kills more than one million people globally each year. Joining me now to talk about aspergillosis, a new kind of...

SCYNEXIS, Inc., a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in its global...

New Jersey based biotechnology company, SCYNEXIS, Inc. announced this week that the U.S. Food and Drug Administration(FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track...